ADPS™ achieved a detection sensitivity of 0.01% without false positives by exclusively amplifying mutated DNA while leaving the wild type intact. This resulting high sensitivity with no false positives facilitates the accurate analysis of patients with first stage cancer.
You can see the operating principle of ADPS™-based liquid biopsy in the following video clip.